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Abstract
The traditional Chinese medicine component dehydrocostuslactone (DHC) isolated from Saussurea costus (Falc.) Lipschitz,
has been shown to have anti-cancer activity. Angiogenesis is an essential process in the growth and progression of cancer.
In this study, we demonstrated, for the first time, the anti-angiogenic mechanism of action of DHC to be via the induction of
cell cycle progression at the G0/G1 phase due to abrogation of the Akt/glycogen synthase kinase-3b (GSK-3b)/cyclin D1 and
mTOR signaling pathway. First, we demonstrated that DHC has an anti-angiogenic effect in the matrigel-plug nude mice
model and an inhibitory effect on human umbilical vein endothelial cell (HUVEC) proliferation and capillary-like tube
formation in vitro. DHC caused G0/G1 cell cycle arrest, which was associated with the down-regulation of cyclin D1
expression, leading to the suppression of retinoblastoma protein phosphorylation and subsequent inhibition of cyclin A and
cdk2 expression. With respect to the molecular mechanisms underlying the DHC-induced cyclin D1 down-regulation, this
study demonstrated that DHC significantly inhibits Akt expression, resulting in the suppression of GSK-3b phosphorylation
and mTOR expression. These effects are capable of regulating cyclin D1 degradation, but they were significantly reversed by
constitutively active myristoylated (myr)-Akt. Furthermore, the abrogation of tube formation induced by DHC was also
reversed by overexpression of Akt. And the co-treatment with LiCl and DHC significantly reversed the growth inhibition
induced by DHC. Taken together, our study has identified Akt/GSK-3b and mTOR as important targets of DHC and has thus
highlighted its potential application in angiogenesis-related diseases, such as cancer.
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Introduction
Angiogenesis, which is the process of formation of new blood
vessels from pre-existing ones, takes place throughout physiolog-
ical development, tissue repair, and reproduction [1]. In
pathological conditions, angiogenesis is also essential for tumor
growth and progression to ensure that more oxygen and nutrients
are delivered from the host’s vascular system. The induction of
tumor vasculatures, termed the angiogenic switch, is initiated by
various growth factors (vascular endothelial growth factor
(VEGF) and basic fibroblast growth factor (bFGF) are the most
commonly ubiquitous) released from tumor cells, and is tightly
regulated by the balance of angiogenic activators and inhibitors
[2]. The angiogenic factors stimulate the degradation of
extracellular matrix components of the parent vessels, which
allow endothelial cells to migrate, proliferate, and form tube-like
structures. After forming new capillary sprouts, the blood vessels
mature. Thus, inhibition of the steps of angiogenesis by blocking
angiogenesis-related proteins could be a strategy to arrest tumor
growth [3].
Akt is a serine/threonine protein kinase activated by growth
factors, which transmits survival signals to downstream effectors.
In endothelial cells, the major growth factor-induced angiogenic
responses are mediated predominantly by Akt signaling [4].
Activation of the Akt signaling pathway is critical for cell
proliferation and growth of endothelial cells. After receptor
stimulation, Akt targets a number of established substrates for
phosphorylation. One of the major effectors downstream of Akt is
glycogen synthase kinase (GSK)-3 [5,6]. Upon the activation of
Akt, Akt inactivates GSK-3b by initiating phosphorylation by at its
serine 9 residue. GSK-3b is thought to regulate cell cycle
progression by phosphorylating cyclin D1 at the threonine 286
residue. This later promotes nuclear export and targets the protein
for ubiquitylation and subsequent degradation by proteasomes
[7,8]. Therefore, growth factors promote cyclin D1 stabilization
and up-regulation through the Akt/GSK-3b pathway [9]. Cyclin
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S phase entry and cell division by binding to cyclin-dependent
kinase (Cdk) 4. Cyclin D1–Cdk4 phosphorylates the retinoblasto-
ma (Rb) protein, upon which E2F is released to transactivate the
genes required for the G1- to S-phase progression [10,11].
Overexpression of cyclin D1 is frequently associated with
tumorigenesis, angiogenesis, and tumor growth [12]. Recently,
accumulating studies have demonstrated that cyclin D1 inhibition
leads to endothelial cell growth arrest, such as cyclin D1 antisense,
which significantly suppressed VEGF-induced in vitro tube
formation and tumor-associated neo-vascularization in the ma-
trigel plug assay and tumor xenograft mouse models [13].
Dehydrocostuslactone (DHC), a sesquiterpene lactone derivative,
is an activecomponentisolated from Saussurea costus(Falc.) Lipschitz,
which shows potential anti-inflammatory [14], hepatoprotective
[15], immunomodulatory [16,17], and cholagogic effects, and is
used in the treatment of ulcers [18]. Recently, DHC has been
reported to potentiate anti-proliferative effects in ovarian cancer
cells [19] and induce apoptosis in various tumors. This occurs as a
result of DHC preventing tumor necrosis factor (TNF)-a-induced
degradation and phosphorylation of IkBa in human promyelocytic
leukemia cells (HL-60) [20], induction of endoplasmic reticulum
stress in hepatoma and lung cancer [21,22], and inhibition of signal
transducers and activators of transcription 3 (STAT3) in breast
cancer [23]. Although DHC has already been shown to be
promising for tumor suppression in vitro and in vivo, whether it can
modulate tumor angiogenesis has not been validated yet. This study
elucidated the molecular mechanism involved in the anti-prolifer-
ative response induced by DHC in endothelial cells. We
demonstrated that DHC inhibits angiogenesis through the Akt/
GSK-3b and mTOR pathways. Furthermore, the in vivo matrigel
plug assay indicated that DHC is a potential anti-angiogenic agent.
Results
Effect of DHC on angiogenesis in vivo
To determine the role of DHC in the regulation of angiogenesis in
vivo, we analyzed matrigel plug formation following subcutaneous
implantation in mice. Matrigel mixed with angiogenic growth factors
induced blood vessel growth and showed blood cell-filled angiogenic
vasculature. In contrast, DHC significantly inhibited neo-vasculari-
zation in a concentration-dependent manner (Figure 1A). Following
Masson’s trichrome staining, the vasculature within the plugs
identified more vessel-like structures within the control group than
in the DHC-treated groups. This study then quantified the vascular
formation in the matrigel by analyzing the hemoglobin content. The
plugs mixed with a variant of growth factors contained 117.3 mg/mL
of hemoglobin, identical to the formation of functional vasculature in
the matrigel (Figure 1B). Co-treatment with DHC reduced the
hemoglobin content in the plugs in a concentration-dependent
manner, demonstrating that DHC has potential inhibitory activity in
growth factors-induced angiogenesis in vivo.
Effect of DHC on angiogenesis in vitro
In angiogenic processes, endothelial cells must undergo ECM
degradation, migration, proliferation, and tube formation to form
new blood vessels [2]. To investigate whether DHC inhibits
angiogenesis through these steps in vitro, the well-established
functional assays were executed. In the crystal violet assay and the
5-bromo-2-deoxyuridine (BrdU) incorporation labeling assay,
DHC (0.3–10 mM) inhibited endothelial growth medium (EGM)-
2–induced cell proliferation and DNA synthesis in a concentra-
tion-dependent manner (GI50=2.4 and 3.0 mM, respectively)
(Figure 2A and 2B). Next, the effects of DHC on the
morphological differentiation and migration of HUVECs were
examined. DHC was found to inhibit the formation of capillary-
like structures induced by EGM-2 in a concentration-dependent
manner. Quantification of the tubes, counted in 5 random fields
under a microscope, showed a 54.0% (P,0.001), 76.2%
(P,0.001), and 98.6% (P,0.001) inhibition following treatment
with 3, 5, and 10 mM DHC, respectively (Figure 2C and 2D).
However, DHC had no significant effect on cell migration in a
transwell assay (Figure 2E and 2F). Overall, these results indicated
that DHC has potent anti-angiogenic activity in vitro and in vivo.
DHC causes G0/G1 phase cell cycle arrest in endothelial
cells
To examine the impaired cell proliferation induced by DHC,
this study utilized flow cytometry to determine whether the DHC-
mediated growth inhibition was due to cell cycle arrest. Treatment
of the cells with DHC (3–10 mM) for 18 h increased the
percentage of HUVECs in the G0/G1 phase and decreased the
population of cells in the S/G2/M phase (Figure 3A, 3B, and 3C).
We also examined the apoptotic effect of DHC under serum
starvation. However, there is no significant difference between
control cells and DHC-treated cells under serum starved condition
(Figure S4). The apoptotic effect in DHC-treated group might be
induced by the serum and growth factors withdrawal. Next, the
effect of DHC on the expression of cell cycle-regulated proteins
involved in the G0/G1 phase was examined. As shown in
Figure 4A and 4B, DHC significantly down-regulated the
expression of cyclin D1 in a time- and concentration-dependent
manners, and the phosphorylation of the downstream effector Rb
was also inhibited. The expression of cyclin A and Cdk2 was
down-regulated in the latter 12 h. However, DHC only slightly
affected Cdk4 at any of the examined time points.
Down-regulation of cyclin D1 by DHC causes growth
inhibition via the Akt/GSK-3b pathway
Previous studies have shown that the serine/threonine kinase
Akt signals in response to a variety of growth factors, including
platelet-derived growth factor (PlGF), bFGF [24,25], and VEGF
[26]. To further delineate the mechanism that underlies the anti-
angiogenic effect of DHC, the effect of DHC on Akt activation was
examined by immunoblot analysis. Treatment with DHC
dramatically suppressed EGM-2–induced Akt phosphorylation in
the time- and concentration-dependent manners (Figure 5A). To
verify that Akt was responsible for the proliferative response and
the regulation of the expression of the cell cycle protein cyclin D1,
we transiently transfected HUVECs with the constitutively active
isoform of Akt and then determined its effect on DHC-induced
growth inhibition. Transfection efficiency was confirmed, as
shown in Figure 5B. LY294002- (an Akt inhibitor, used as a
positive control) and DHC-treated HUVECs over-expressing Akt
exhibited a highly significant increase in the expression of cyclin
D1 relative to the vector-treated group (Figure 5C).
Akt signaling negatively regulates GSK-3b activity by phos-
phorylating Ser-9, and GSK-3b was shown to regulate the cell
cycles through cyclin D1 proteasome-mediated degradation [8].
This study investigated whether the inhibition of Akt phosphor-
ylation by DHC led to a decrease in GSK-3b phosphorylation
levels and consequently contributed to growth inhibition. As
shown in Figure 5D, treatment with DHC inhibited GSK-3b
phosphorylation in the concentration- and time-dependent
manners. However, DHC-treated cells combined with the over-
expression of Akt increased the phosphorylation of GSK-3b
compared with the vector group. As determined using the crystal
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be reversed by myristoylated (myr)-Akt treatment (Figure 6A).
Over-expression of Akt in HUVECs also partial reversed the
abrogation of tube formation induced by DHC (Figure 6B). To
verify whether GSK-3bis involved as a downstream effecter of Akt
in the anti-angiogenic process of DHC, we treated HUVECs with
LiCl, a GSK-3b activity inhibitor. Co-treatment of the LiCl with
DHC significantly reversed the growth inhibition by approxi-
mately 50% of the DHC-treated cells (Figure 6C). Taken together,
these results indicated that inhibition of the Akt/GSK-3b/cyclin
D1 pathway plays an important role in DHC-induced growth
inhibition and abrogation of tube formation in HUVECs.
DHC suppresses expression of cyclin D1 in an mTOR-
dependent manner
Akt signaling is required for growth factor-induced activation of
mammalian target of rapamycin (mTOR)-C1, and the activity of
mTORC1 is impaired in Akt-deficient cells [27,28]. The
activation of mTORC1 also leads to the phosphorylation of 4-
emopamil-binding protein (EBP)-1 and, therefore, activates eIF4E
to up-regulate the translational levels of cyclin D1 [29]. To
evaluate the contribution of mTORC1 in the DHC-induced
downregulation of cyclin D1 in HUVECs, the downstream
signaling effectors of mTORC1 were examined. We found that
DHC effectively suppressed EGM-2-induced phosphorylation of
the mTOR signaling cascade, including mTOR, p70S6K, 4EBP,
and eIF4E, in a time-dependent manner (Figure 7A). DHC also
inhibited the phosphorylation of mTOR downstream molecules in
a concentration-dependent manner (Figure 7A). In HUVECs
overexpressing Akt, the inhibitory effects of DHC on the
phosphorylation of mTOR downstream signaling molecules had
significantly reversed protein expression relative to the vector
group (Figure 7B). Using the crystal violet assay, the co-treatment
of rapamycin and DHC increased the growth inhibition effect
Figure 1. DHC inhibits angiogenesis in a mouse matrigel model. C57BL/6 mice were injected subcutaneously with matrigel mixed with or
without DHC (1 mM and 10 mM). A, upper panel, plugs were excised from the mice after a week and photographed. Bottom panel, histological analysis
was performed using Masson-Trichrome staining from the excision of matrigel plug. B, Quantification of the hemoglobin content of matrigel plugs by
spectrophotometermeasuredat540 nm.Datarepresentthemean6SEMfromfiveindependentexperiments.*P,0.05and***P,0.001versuscontrol.
doi:10.1371/journal.pone.0031195.g001
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that the Akt/mTOR signaling pathway could be involved in the
growth arrest induced by DHC inhibition of cyclin D1.
Discussion
Tumor progression and metastatic shedding are dependent on
angiogenesis [30]. Thus, in recent years, the development of anti-
angiogenic agents has become attractive. Additionally, natural
products have been reported to have a cytotoxic effect on the
normal cell cycle. However, thus far, out of 22 anti-angiogenic
agents, there are only 11 natural products or natural modified
compounds have been under clinical trials [31]. This study found
that DHC, a component of traditional Chinese medicine, has anti-
angiogenic effects in vivo and in vitro. First, this study utilized the
matrigel plug assay, which provided strong evidence that DHC
inhibited angiogenesis in vivo in a dose-dependent manner.
Previous studies have revealed that DHC suppresses the growth
of various human tumors in xenograft mouse models [21,22,23].
Therefore, the inhibition of angiogenesis by DHC seems to be one
of the main mechanisms that may hinder tumor progression. A
series of in vitro assays established that the inhibition of EGM-2-
induced tube formation and endothelial cell proliferation were
consistent with this study’s in vivo result. In contrast, DHC had no
significant inhibitory effect on cell migration in the transwell assay.
Using the western blot, activation of p38 and ERK1/2 signaling
has been observed when HUVECs were treated with DHC (figure
S1B). We employed another system, a scratch wound healing assay
to double confirm the effect of DHC on HUVECs migration.
However, only combined treatment with p38 and DHC
significantly inhibited HUVECs migration (figure S1A). The result
indicated that even with inhibition of PI3K/Akt pathways, p38
Figure 3. Effect of DHC on cell cycle. A, HUVECs were starved for 24 h, and then were treated with or without DHC (3–10 mM) for 18 hr. After cells
were labeled with propidium iodide, DNA content was analyzed by flow cytometry. B and C, cell population in G0/G1 and S/G2/M phase were
quantified. Data represent the mean 6 SEM from four independent experiments. * P,0.05, ** P,0.01 and *** P,0.001 versus control.
doi:10.1371/journal.pone.0031195.g003
Figure 2. Impairment of in vitro angiogenesis by DHC. A, HUVECs were treated with or without DHC (0.3–10 mM) in EGM-2 medium. After 72 h
of incubation, cells were stained with crystal violet and determined the inhibition of cell proliferation by the absorbance at 550 nm. B, DNA synthesis
was assessed by BrdU incorporation assay. C, representative photographs of capillary-like structures formation of CTL and DHC-treated HUVECs on
matrigel under microscope (magnification is X100). D, Quantification of the total tube length of capillary-like structures by image analysis software.
Data represent the mean 6 SEM from three independent experiments. ** P,0.01 and *** P,0.001 versus control. E, effect of DHC on cell migration
using a transwell assay. F, the graph shows quantitative analysis of the migrated cell numbers in tranwell assay. Data represent the mean 6 SEM from
three independent experiments. ## P,0.01 versus basal.
doi:10.1371/journal.pone.0031195.g002
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while Akt signaling is inhibited. Taken together, we suggested that
DHC blocked blood vessel formation by the selective inhibition of
endothelial cell growth and capillary-like structure formation.
Cell proliferation is a critical event in the process of
angiogenesis. This study found that DHC delayed the transition
of HUVECs from the G0/G1 phase to the S phase. These results
are consistent with those of a previous study, which found that
DHC treatment induced growth inhibition in breast cancer [23].
Cyclin D1, known as an essential mitogenic signal sensor and cell
cycle regulator, binds to CDK4 and forces cells to enter the
proliferative stage of cell cycle from the G0 phase. Cyclin D1
reportedly plays an important role in endothelial cells. More
recent studies have demonstrated that overexpression of cyclin D1
is linked to the development of various cancers [12]. Therefore,
strategies to down-regulate cyclin D1 expression were reported to
inhibit tumor angiogenesis in vitro and in vivo [13,32]. Our results
indicated that DHC significantly inhibited cyclin D1 expression
within 3 h of DHC treatment in a concentration- and time-
dependent manner. Other cell cycle regulators appeared to be
down-regulated after 12 h of DHC treatment. This study
concluded that DHC-induced growth arrest of HUVECs via the
down-regulation of cyclin D1, and it might play an important role
in the suppression of angiogenesis.
Evidence implies that Akt signaling is essential for normal cellular
G1/S phase transition and cell proliferation in endothelial cells
[33,34,35,36]. Data from preclinical studies suggest that inhibitors
of the PI3K/Akt signaling pathway have been reported to be potent
anti-angiogenic agents and contribute to the inhibition of tumor
growth [37,38,39,40,41]. Upon growth factor stimulation, Akt is
activated immediately in endothelial cells. The phosphorylation of
Akt at the T308 residue was mediated by PDK1, whereas
phosphorylation at the S473 residue was attributed to mTORC2
[42]. The two phosphorylation sites are equally important, and lead
to full activation of the Akt protein kinase. The major effectors
downstream of Akt are mTORC1 and GSK-3b. The active
mTORC1 induces cyclin D1 expression to promote cell growth by
direct phosphorylation of the substrates, S6K1 and 4EBP1, both of
which are translational regulators [29,43]. Alternatively, Akt
phosphorylates and inhibits GSK-3b activity to prevent cyclin D1
degradation [7,8]. Therefore, inhibition of the Akt signaling
pathway resulted in the down-regulation of cyclin D1 via a GSK-
3b-degradation and mTORC1-dependent translation pathway.
Most importantly, this study has identified, for the first time, the
effect of DHC on the Akt/GSK-3b/cyclin D1 pathway. Addition-
ally, DHC inhibited Akt phosphorylation at Ser473 in HUVECs, in
a concentration- and time- dependent manner, suggesting that
DHC is a possible competitor of mTORC2. As mentioned above,
the activation of Akt is induced by various growth factors in a PI3K-
dependentmanner.Inthisstudy,wefoundthattreatmentwithmyr-
Akt greatly increased the amount of Ser473 Akt present in
HUVECs. Our results are similar to those for treatment with the
PI3K inhibitor LY294002. We also performed the Akt kinase
activity assay. However, DHC did not inhibit the ability of Akt to
phosphorylate its substrate (figure S2). Therefore, DHC is a possible
potent PI3K kinase or PDK1 kinase inhibitor that could display
anti-angiogenic effects in vitro and in vivo.
Previous studies have shown that mTORC1 activation is not
only under the regulation of Akt signaling but is also sensitive to
growth factors, hypoxia, low energy, and amino acids, and it
integrates these inputs to regulate cell responses [44]. However,
the results showed that myr-Akt can reverse the inhibitory effects
Figure 4. Effect of DHC on expression levels of cyclins and CDKs. A, after starvation for 24 hr, HUVECs were pretreated with or without DHC
for 60 min and then incubated with EGM-2 at indicated time. Cells were harvested, analyzed by western blot and probe with antibodies. B, cyclin D1
expression was inhibited by DHC in a concentration dependent manner. Actin expression served as a loading control. Data represent from three
independent experiments.
doi:10.1371/journal.pone.0031195.g004
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mTOR translational pathway is another important target
responsible for DHC-induced cyclin D1 down-regulation. Previ-
ous studies have reported other targets of DHC in cancer cells
including NF-kB, STAT3, and induction of ER stress [20,21,23].
In addition, activation of NF-kB has been known to regulate the
expression of genes encoding angiogenic factors. Therefore, the
contribution of these targets to the anti-angiogenic effect of DHC
cannot be excluded. However, overexpression of myr-Akt
significantly rescued the growth inhibition induced by DHC,
suggesting that DHC-induced inhibition of Akt activation is
responsible for the anti-proliferative effect observed in HUVECs.
Thus, the mechanisms of DHC mentioned above may probably
synergistically exhibit anti-angiogenic activity in vitro and in vivo.
In conclusion, this study discovered a novel mechanism by
which DHC impairs angiogenesis induced by growth factors.
DHC-induced cell cycle in HUVECs was arrested at the G0/G1
phase, followed by subsequent inhibition of angiogenesis in vitro
and in vivo by targeting the Akt/GSK-3b and mTOR pathway.
Thus, the results generated by this study suggest that DHC is a
promising traditional Chinese medicine component for therapeu-
tic intervention against angiogenesis-related diseases.
Materials and Methods
Reagents
Dehydrocostuslactone (DHC) was purchased from Wako Pure
Chemical Industries, Ltd. (Osaka, Japan). Propidium iodide was
Figure 5. Cyclin D1 is a critical target of DHC-mediated cell cycle arrest through Akt/GSK-3b pathway. A, Western blot analysis of Akt
phosphorylation inhibited by DHC with the indicated times and concentrations. B, HUVECs were transfected with either vector or myr-Akt, starved for
24 hr, and then pretreated with DHC for 1 hr followed by incubation in EGM-2 medium for 10 min. Cells were harvested and analyzed protein
expression by western blot. C and D, western blot analysis of cyclin D1 expression and GSK-3b phosphorylation in HUVECs transfected with the
indicated plasmids and then treated with DHC (3 and 5 mM) and Ly294002 (10 mM) for 6 hr. Data represent from three independent experiments.
doi:10.1371/journal.pone.0031195.g005
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penicillin, streptomycin and the other tissue culture reagents were
obtained from Gibco BRL Life Technologies (Grand Island, NY).
Endothelial cell basal medium (EBM) and endothelial growth
factors (EGM-2) were purchased from Clonetics (BioWhittaker,
Walkersville, MD). The antibody against cyclin D was purchased
from Calbiochem (San Diego, CA). Antibodies against CDK2,
CDK4, cyclin A were purchased from Santa Cruz Biotechnology.
Antibodies against p-mTOR (Ser2448), p-p70S6K (Thr421/
Ser424), p-eIF4E (Ser209), p-4EBP1 (Thr37/46), p-GSK-3b
Figure 7. Effect of DHC on mTOR signaling downstream pathway. A, Western blot analysis of phosphorylation of mTOR, p70S6K, eIF4E and
4EBP in HUVECs treated with DHC for the indicated times and concentrations. B, after transfected with the indicated plasmids, HUVECs were starved
for 24 hr and then pretreated with DHC followed by 10 min of EGM-2 incubation. Phosphorylation of mTOR and 4EBP were analyzed by western blot.
Data represent from three independent experiments.
doi:10.1371/journal.pone.0031195.g007
Figure 6. DHC inhibited cell proliferation and tube formation through Akt/GSK-3b pathway A, crystal violet assay. Treatment of vector
group with DHC (3 mM) in EGM-2 medium significantly decreased cell proliferation numbers compared with untreated vector group. Akt
overexpression significantly increased cell proliferation in DHC-treated group. B, tube formation assay. Treatment of vector group with DHC (3 mM)
abrogated tube formation compared with vector control group. Akt overexpression partial reversed the inhibitory effect. C, crystal violet assay.
HUVECs were treated with DHC (3 mM) and/or LiCl (10 mM). NaCl (10 mM) was as an osmolality control. Data represent from three independent
experiments.
doi:10.1371/journal.pone.0031195.g006
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The antibody against p-Akt (Ser473) was purchased from
Epitomics (San Francisco, CA, USA).
Cell culture
Human umbilical vein endothelial cells (HUVEC) (ScienCell
Research Laboratories, San Diego, CA) were grown to confluence
on 1% gelatin, and maintained in endothelial cell medium (ECM)
(ScienCell Research Laboratory) supplemented with 5% FBS, 1:5
Penicillin/Streptomycin (ScienCell Research Laboratory) and 1:5
endothelial cell growth supplements (ECGs) (ECGs; Upstate
Biotechnology Inc., Lake Placid, NY). Before treatment of
dehydrocostuslactone in EGM-2 medium, HUVECs were starved
for 24 hours in EBM-2 medium. All of the following experiments
were performed in this medium.
In vivo matrigel plug assay
All animal experiments followed ethical standards, and
protocols has been reviewed and approved by Animal Use and
Management Committee of National Health Research Institutes
(NHRI-IACUC-099003-A). In vivo angiogenesis assay was deter-
mined as blood vessel growth in the exogenous matrigel plug
injected in C57BL/6 mice (6 weeks old). Briefly, matrigel (BD
Bioscience) was mixed with heparin (10 units/ml), VEGF (40 ng/
ml), IGF-1 (40 ng/ml), EGF (40 ng/ml), bFGF (40 ng/ml) and
with or without DHC and the resulting mixture was injected
subcutaneously into the mice abdomens. After seven days, the
animals were sacrificed and the matrigels were carefully dissected
and photographed. To quantify the blood vessel formation,
hemoglobin content was analyzed by Drabkin’s reagent kit
(Sigma).
Crystal violet assay
The HUVECs were seeded into 96-well culture plates (5.0610
3
cells per well) in triplicate. Twenty-four hours later, the culture
medium was removed and replaced with fresh EGM-2 medium
containing DHC at various concentrations. After 72 hours of
incubation at 37uC, the cells were stained with 0.1% crystal violet/
20% methanol for 10 minutes. Then the dye was eluted by 0.1 M
sodium citrate/75% ethanol, and absorbance is measured at
540 nm with an ELISA reader.
DNA synthesis assay
Cell growth was measured by 5-bromo-2-deoxyuridine (BrdU)
incorporation into newly synthesized DNA of proliferating
HUVECs with the colorimetric ELISA kit (Amersham Bioscienc-
es, Piscataway, NJ). Briefly, cells were seeded at 5.0610
3 cells per
well into 96-well culture plates in triplicate and starved with EBM-
2 medium overnight. Then the cells were treated with or without
DHC and EGM-2 medium for 48 hours. To label the synthesized
DNA, 10 mM BrdU was added to cultures for the last 18 hours
before staining. After incubation, the cells were fixed and detected
with anti-BrdU mAb according to the manufacturer’s instructions.
The absorbance was measured at 450 nm.
Endothelial cell migration assay
The assessment of HUVEC cells migration was performed by
using Transwell (Corning) with 8 mM pore sized filters. First,
HUVECs (75000 cells/100 ml) were pretreated with DHC for
30 minutes and then plated in the upper chamber of the
Transwell. To allow for cell migration, EGM-2 medium was
added to the lower chamber as chemoattractant. After 6 hours of
incubation at 37uC, the nonmigrated cells in the upper chamber
were wiped away with cotton swabs and cells that migrated to the
lower surface of the filters were fixed and stained with crystal
violet, and photographed with a microscope. The filters were cut
from the chamber and then eluted with 0.1 M sodium citrate
solution to quantify the migrated cells. The absorbance was
measured at 540 nm.
Capillary tube formation assay
The assay was performed by utilizing Matrigel (Growth factor
reduced, BD Biosciences) added to a 96 well plate and the gel
allowed to solidify at 37uC for 1 hour. Subsequently, HUVECs
were harvested after trypsin treatment, were then resuspended in
EGM-2 medium in the presence or absence of DHC at various
concentrations, seeded onto the layer of Matrigel at a cell number
of 1.75610
4/per well. After 6 hours of incubation, tubular
network structures were visualized and photographed under a
phase contrast microscope. The relative lengths of tubes were
quantified by Image analysis software (Image-ProH Plus).
Flow cytometric analysis
HUVECs grown to 70% confluence were starved with EBM-2
medium for 24 hours and then replaced with EGM-2 medium
with or without DHC for 18 hours. After trypsinized and fixed in
ice-cold 75% methanol for a minimum of one hour at 220uC,
cells were washed with PBS and resuspended in 0.2 ml DNA
extraction buffer (0.2 M Na2HPO4, 0.1 M citric acid; pH 7.8) for
30 minutes. Then the cells were stained with propidium iodide
solution (PI; 100 mg/ml RNase, 80 mg/ml propidium iodide, 0.1%
Triton X-100) in PBS. Cell cycle distribution was determined by
FACScan flow cytometry, and data analysis was performed with
CellQuest software (BD Biosciences).
Western blotting
HUVECs were harvested after treatment of DHC in EGM-2
medium at an indicated time, and then total cell lysate were
prepared in a modified RIPA buffer (150 mM NaCl, 1 mM
EDTA, 1% Nonidet p-40, 0.5% sodium deoxycholate, 0.1% SDS,
20 mM Tris, pH 8.0) with protease inhibitors (1 mg/ml aprotinin,
1 mg/ml leupeptin, 0.5 M NaF, 0.5 M Na3VO4, 1 mM phenyl-
methylsulfonyl fluoride). The cell extract proteins were separated
by 8%–12% polyacrylamide gel electrophoresis followed by
electroblotting onto polyvinylidene difluoride membranes. Mem-
branes were subsequently blocked with 5% nonfat milk, washed
with PBS, incubated with antibodies and detected utilizing an
enhanced chemiluminescence (ECL) detection system.
Statistical analysis
The significance of differences in vivo data were analyzed by the
Mann-Whitney U test; others represent the mean and SEM of at
least three independent experiments. Statistical analysis was
performed by the t-test, and P values less than 0.05 (* P,0.05,
** P,0.01, *** P,0.001) were considered significant.
Supporting Information
Figure S1 Effect of DHC on HUVECs migration. A,
HUVECs migration after DHC treatment was accessed by
wound-healing assay. Upon reaching 95% confluence, the
HUVEC monolayer was scratched and cell debris was removed.
Cells were cultured with EGM-2 medium and preteated with
PD98059 (10 mM) or SB203580 (10 mM) for 30 min, and then
cells were treated with DHC (3 or 5 mM). After incubation for
16 h, cells were stained with crystal violet and photographed. B,
Western blot analysis of the protein expression of p-p38, p-ERK1/
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concentrations. Data represent from three independent experi-
ments.
(PDF)
Figure S2 DHC did not inhibit Akt kinase activity. Akt
Kinase activity kit was purchased from Enzo Life Sciences. Data
represent from three independent experiments.
(PDF)
Figure S3 Rapamycin increased the anti-proliferative
effect induced by DHC. Crystal violet assay. HUVECs were
treated with DHC (3 mM) and/or rapamycin (3 mM). Inhibition of
mTOR activity increased the anti-proliferative effect of DHC.
Data represent from three independent experiments.
(PDF)
Figure S4 Effect of DHC on early and late stage of
HUVECs apoptosis was detected by flow cytometry with
Annexin-V-FITC/PI dual staining. A representative histo-
gram of flow cytometric analysis using double staining with
annexin-V (FITC-A) and PI (PE-A). HUVECs were treated with
DHC (5 mM) in EBM-2 basal medium for 4 hr or 24 hr. The
lower right quadrants represent the cells in the early stage of
apoptosis. The upper right plus left quadrants contain the cells in
the late stage of apoptosis and necrosis. Data represent from three
independent experiments.
(PDF)
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